For instance, ATN-292 reduces migration in human pancreatic cancer cells by blocking the uPA to uPAR binding (253), and a novel anti-uPAR monoclonal antibody has shown antitumor effects in gastric cancer by disrupting this interaction (254). Here, PLAUR is linked to pancreatic neoplasm.